Abstract
Puma Biotechnology, the new start-up of the founder of Cougar Biotechnology, has in-licensed worldwide development and commercialisation rights to Pfizer’s investigational pan-HER inhibitor neratinib following a pipeline review at the big pharma company. The drug is currently being studied in Phase II and Phase III trials in patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer and Puma has raised approximately US$55 M in a private placement to help fund its further development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
